S&P 500   3,368.02 (+0.22%)
DOW   28,025.18 (+0.84%)
QQQ   268.05 (-0.84%)
AAPL   446.05 (-1.08%)
MSFT   207.00 (-0.60%)
FB   264.07 (+0.41%)
GOOGL   1,498.42 (+0.11%)
AMZN   3,121.43 (-0.85%)
NVDA   440.82 (-1.29%)
CGC   17.50 (-2.40%)
BABA   250.14 (+0.81%)
TSLA   1,391.89 (-1.88%)
GE   6.82 (+2.25%)
MU   48.83 (-0.65%)
AMD   78.62 (-4.40%)
T   30.47 (+0.89%)
F   7.34 (+3.53%)
ACB   10.08 (-1.37%)
GILD   68.33 (-0.26%)
NFLX   472.44 (-2.26%)
DIS   131.82 (+2.35%)
BAC   27.46 (+3.35%)
BA   186.57 (+3.99%)
S&P 500   3,368.02 (+0.22%)
DOW   28,025.18 (+0.84%)
QQQ   268.05 (-0.84%)
AAPL   446.05 (-1.08%)
MSFT   207.00 (-0.60%)
FB   264.07 (+0.41%)
GOOGL   1,498.42 (+0.11%)
AMZN   3,121.43 (-0.85%)
NVDA   440.82 (-1.29%)
CGC   17.50 (-2.40%)
BABA   250.14 (+0.81%)
TSLA   1,391.89 (-1.88%)
GE   6.82 (+2.25%)
MU   48.83 (-0.65%)
AMD   78.62 (-4.40%)
T   30.47 (+0.89%)
F   7.34 (+3.53%)
ACB   10.08 (-1.37%)
GILD   68.33 (-0.26%)
NFLX   472.44 (-2.26%)
DIS   131.82 (+2.35%)
BAC   27.46 (+3.35%)
BA   186.57 (+3.99%)
S&P 500   3,368.02 (+0.22%)
DOW   28,025.18 (+0.84%)
QQQ   268.05 (-0.84%)
AAPL   446.05 (-1.08%)
MSFT   207.00 (-0.60%)
FB   264.07 (+0.41%)
GOOGL   1,498.42 (+0.11%)
AMZN   3,121.43 (-0.85%)
NVDA   440.82 (-1.29%)
CGC   17.50 (-2.40%)
BABA   250.14 (+0.81%)
TSLA   1,391.89 (-1.88%)
GE   6.82 (+2.25%)
MU   48.83 (-0.65%)
AMD   78.62 (-4.40%)
T   30.47 (+0.89%)
F   7.34 (+3.53%)
ACB   10.08 (-1.37%)
GILD   68.33 (-0.26%)
NFLX   472.44 (-2.26%)
DIS   131.82 (+2.35%)
BAC   27.46 (+3.35%)
BA   186.57 (+3.99%)
S&P 500   3,368.02 (+0.22%)
DOW   28,025.18 (+0.84%)
QQQ   268.05 (-0.84%)
AAPL   446.05 (-1.08%)
MSFT   207.00 (-0.60%)
FB   264.07 (+0.41%)
GOOGL   1,498.42 (+0.11%)
AMZN   3,121.43 (-0.85%)
NVDA   440.82 (-1.29%)
CGC   17.50 (-2.40%)
BABA   250.14 (+0.81%)
TSLA   1,391.89 (-1.88%)
GE   6.82 (+2.25%)
MU   48.83 (-0.65%)
AMD   78.62 (-4.40%)
T   30.47 (+0.89%)
F   7.34 (+3.53%)
ACB   10.08 (-1.37%)
GILD   68.33 (-0.26%)
NFLX   472.44 (-2.26%)
DIS   131.82 (+2.35%)
BAC   27.46 (+3.35%)
BA   186.57 (+3.99%)
Log in

NASDAQ:CPRXCatalyst Pharmaceuticals Stock Price, Forecast & News

$3.39
-0.87 (-20.42 %)
(As of 08/11/2020 02:39 PM ET)
Add
Compare
Today's Range
$3.39
Now: $3.39
$3.96
50-Day Range
$4.05
MA: $4.67
$5.08
52-Week Range
$2.55
Now: $3.39
$7.67
Volume7.07 million shs
Average Volume1.54 million shs
Market Capitalization$350.64 million
P/E Ratio8.48
Dividend YieldN/A
Beta1.86
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with New York University, the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc.; and collaboration agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Read More
Catalyst Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.00 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CPRX
CUSIPN/A
Phone305-420-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$102.31 million
Cash Flow$0.26 per share
Book Value$0.85 per share

Profitability

Net Income$31.88 million

Miscellaneous

Employees51
Market Cap$350.64 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$3.39
-0.87 (-20.42 %)
(As of 08/11/2020 02:39 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions

How has Catalyst Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CPRX stock has decreased by 3.7% and is now trading at $3.3901.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Catalyst Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Catalyst Pharmaceuticals
.

When is Catalyst Pharmaceuticals' next earnings date?

Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Catalyst Pharmaceuticals
.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) announced its quarterly earnings results on Monday, August, 10th. The biopharmaceutical company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.01. Catalyst Pharmaceuticals had a return on equity of 52.28% and a net margin of 36.09%.
View Catalyst Pharmaceuticals' earnings history
.

What price target have analysts set for CPRX?

5 analysts have issued 1-year price targets for Catalyst Pharmaceuticals' stock. Their forecasts range from $7.00 to $12.00. On average, they anticipate Catalyst Pharmaceuticals' share price to reach $9.20 in the next twelve months. This suggests a possible upside of 171.4% from the stock's current price.
View analysts' price targets for Catalyst Pharmaceuticals
.

Has Catalyst Pharmaceuticals been receiving favorable news coverage?

News coverage about CPRX stock has been trending neutral recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Catalyst Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about Catalyst Pharmaceuticals
.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totaling 12,690,000 shares, an increase of 12.1% from the January 15th total of 11,320,000 shares. Based on an average daily trading volume, of 2,330,000 shares, the days-to-cover ratio is presently 5.4 days. Approximately 13.3% of the shares of the stock are sold short.
View Catalyst Pharmaceuticals' Short Interest
.

Who are some of Catalyst Pharmaceuticals' key competitors?

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Amarin (AMRN), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Verastem (VSTM), SCYNEXIS (SCYX), Viking Therapeutics (VKTX) and Micron Technology (MU).

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the following people:
  • Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO (Age 72)
  • Ms. Alicia Grande, VP, Treasurer & CFO (Age 48)
  • Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 57)
  • Mr. Brian Elsbernd, Chief Legal & Compliance Officer (Age 55)
  • Dr. Gary Ingenito, Chief Medical Officer & Head of Regulatory Affairs (Age 63)

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Gables Capital Management Inc. (0.49%), Cadence Capital Management LLC (0.32%), Hancock Whitney Corp (0.31%), Russell Investments Group Ltd. (0.30%), Raymond James Financial Services Advisors Inc. (0.24%) and Swiss National Bank (0.21%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus, Gary Ingenito and Patrick J Mcenany.
View institutional ownership trends for Catalyst Pharmaceuticals
.

Which institutional investors are selling Catalyst Pharmaceuticals stock?

CPRX stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Leap Investments LP, Strs Ohio, Russell Investments Group Ltd., and Gables Capital Management Inc..
View insider buying and selling activity for Catalyst Pharmaceuticals
.

Which institutional investors are buying Catalyst Pharmaceuticals stock?

CPRX stock was bought by a variety of institutional investors in the last quarter, including Hancock Whitney Corp, LSV Asset Management, Wedge Capital Management L L P NC, Rafferty Asset Management LLC, Seizert Capital Partners LLC, XML Financial LLC, Swiss National Bank, and Creative Planning. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus, and Patrick J Mcenany.
View insider buying and selling activity for Catalyst Pharmaceuticals
.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $3.39.

How big of a company is Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals has a market capitalization of $350.64 million and generates $102.31 million in revenue each year. The biopharmaceutical company earns $31.88 million in net income (profit) each year or $0.30 on an earnings per share basis. Catalyst Pharmaceuticals employs 51 workers across the globe.

What is Catalyst Pharmaceuticals' official website?

The official website for Catalyst Pharmaceuticals is www.catalystpharma.com.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.